Pharma Pulse 4/18/24: Certain Biotech Investors Get an Early Look at Results, An Ethical Outlook for Obesity Drugs & more

Check out our coverage from LogiPharma Europe 2024

An Ethical Outlook for Obesity Drugs

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses what to expect from the obesity space in the next five years.

It's Not Just Congress. There's Plenty of State-Level Action on PBMs, Drug Costs and Prices | AMCP 2024

Adam Colborn outlined four trends in state-level action on pharmacy benefit managers and drugs in an interview prior to this presentation at the annual meeting of Academy of Managed Care Pharmacy.

Certain Biotech Investors Get an Early Look at Results. Is That Fair?

Private investments in public equities, or PIPEs, are all the rage in biotech, but some investors resent the sharing of nonpublic information.

DoseMe Expands Global Footprint as Premier Hospitals and Cancer Centers across Australia Continue to Adopt Bayesian Dosing

Healthcare organizations utilizing DoseMeRx are experiencing improved patient outcomes and hospital economic health.

Hadi Rizek on LinkedIn:

Thanks Nicholas Saraceno and Pharmaceutical Commerce Magazine for capturing our messsge - spot on!

We are on an excited journey to challenge status quo of supply chain operation. The great feedback and reflections from the session are just proof of that.

#dashboardsarenotenough
#digitalsupplychain
#logipharmaeurope2024

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs